Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session Across the COAST 1, COAST 2, and SHORE phase 3 studies, amlitelimab, dosed...
-
Dublin, March 27, 2026 (GLOBE NEWSWIRE) -- The "Bispecific T-Cell Engagers Market Report 2026" has been added to ResearchAndMarkets.com's offering. The bispecific T-cell engagers market is...
-
Dublin, March 27, 2026 (GLOBE NEWSWIRE) -- The "Pelvic Cancer Induced Hemorrhagic Cystitis Market Report 2026" has been added to ResearchAndMarkets.com's offering. The pelvic cancer induced...
-
Dublin, March 27, 2026 (GLOBE NEWSWIRE) -- The "Clinical Nutrition for Diabetes Care Market Report 2026" has been added to ResearchAndMarkets.com's offering. The clinical nutrition for diabetes...
-
La formulation sous-cutanée de Sarclisa de Sanofi, administrée via un injecteur portable, est recommandée par le CHMP pour approbation dans l'UE dans le traitement du myélome multiple ...
-
Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma Recommendation based on positive results demonstrating...
-
Pruritus therapeutics market to reach $15.58 Bn by 2035, driven by rising skin disorders, strong biologics pipeline, and expanding global treatment demand.
-
The global market for neuroprotective agents was valued at $41.2 billion in 2024 and is expected to reach $60.9 billion by the end of 2030.
-
FOSTER CITY, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer,...
-
BOSTON, March 25, 2026 (GLOBE NEWSWIRE) -- NodThera, the leading clinical-stage NLRP3 company developing a portfolio of best-in-class brain-penetrant and immune-targeted oral inhibitors to address...